Duktus bağımlı konjenital kalp hastalığı olan bir term yenidoğanda invajinasyon

Öz

Prostaglandin E1 infüzyonu, duktus bağımlı konjenital kalp hastalığı olan yenidoğanlarda ameliyat edilinceye kadar duktusu açık tutmak amacıyla yaygın olarak kul­lanılmaktadır. Prostaglandin E1 yaşam kurtarıcı bir ilactır ancak ateş, apne, bradikardi, hipotansiyon, konvülziyon, ödem ve kortikal hiperostoz gibi birçok yan etkiye de yol açabilir. İlacın doz azaltmasına yanıt veren ishal dışın­da gastrointestinal sistemle ilgili önemli yan etkisi rapor edilmemektedir. Bu yazıda duktus bağımlı konjenital kalp hastalığı olan ve olasılıkla prostaglandin tedavisi ile te­tiklenen intestinal invajinasyon gelişen bir olgu sunuldu.

Anahtar Kelimeler

• Prostaglandin E1, yenidoğan, gast­rointestinal

Intussusception in a term newborn with duct-dependent congenital heart disease

Öz

Prostaglandin E1 infusion is widely used to maintain pa­tency of ductus arteriosus in newborns with duct-depen­dent congenital heart disease until surgery. Prostaglandin E1 is a lifesaving drug, but it has many side effects includ­ing fever, apnea, bradycardia, hypotension, convulsion, edema, and cortical hyperostosis. The gastrointestinal tract has not been recognized as a major site of serious adverse effects of prostaglandin E1 infusion, although diarrhea is a well-recognized side effect that usually re­sponds to dose reduction. In this report, we present a case of intestinal intussusception presumably induced by prostaglandin therapy in a newborn with duct-dependent congenital heart disease.

Anahtar Kelimeler

• Prostaglandin E1, newborn, gastrointestinal

Kaynakça

1. Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. Can J Physiol Pharmacol 1973;51:220-5.
2. Heymann MA. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease. Am Heart J 1981;101:837-43.
3. Lewis AB, Freed MD, Heymann MA, Roehl SL, et al. Side effects of therapy with prostaglandin E1 in infants with crit- ical congenital heart disease. Circulation 1981;64:893-8.
4. Peled N, Dagan O, Babyn P, et al. Gastric-outlet obstruc- tion induced by prostaglandin therapy in neonates. N Engl J Med 1992;327:505-10.
5. Wilson DE. Prostaglandins: their actions on the gastrointesti- nal tract. Arch Intern Med 1974;133:112-8.
6. Tytgat GN, Offerhaus GJ, van Minnen AJ, et al. Influence of oral 15(R)-15-methyl prostaglandin E2 on human gastric mucosa. A light microscopic, cell kinetic, and ultrastruc- tural study. Gastroenterol 1986;90:1111-20.
7. Nissan A, Zhang JM, Lin Z, et al. The contribution of inflam- matory mediators and nitric oxide to lipopolysaccharide- induced intussusception in mice. J Surg Res 1997;69:205-7.
8. Pavri DR, Marshall DG, Armstrong RF, et al. Intrauterine in- tussusception: case report and literature review. Can J Surg 1983;26:376-8.

9. Kobayashi N, Aida N, Nishimura G, et al. Acute gastric out- let obstruction following the administration of prostaglan- din: an additional case. Pediatr Radiol 1997;27:57-9.